

November 14, 2019

To,
The Manager
Listing Department,
The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400051

Dear Sir/ Madam,

Trading Symbol: ZOTA

Sub: Outcome of Board Meeting held on Thursday, November 14, 2019

Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the captioned subject, we would like to inform you that the Board of Directors of Zota Health Care Limited (the "Company") in its Meeting held on Thursday, November 14, 2019 at 02:00 P.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat – 395002 have, *inter alia*, discussed and approved the following business:

1. Considered and approved unaudited standalone and consolidated financial results for the quarter and half year ended on September 30, 2019 along with Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (*Annexure – I*).

Further, unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company is listed i.e. at www.nseindia.com and on Company's website at www.zotahealthcare.com

The Board meeting concluded at 07:00 P.M.

This is for your information and record.

Thanking you,

Yours faithfully,

For Zota Health Care Limited



Ashvin Variya
(Company Secretary & Compliance Officer)

Place: Surat



Encl: a/a

Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Standalone Unaudited Quarterly Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

The Board of Directors of
Zota Health Care Limited


1. We have reviewed the accompanying statement of unaudited financial results of **Zota Health Care Limited** (the "Company") for the **quarter and half year ended September 30, 2019** (the "Statement") attached herewith, being submitted by the Company pursuant to requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Regulation").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Attention is drawn to Note no.3 of the Statement which states that the Comparative figures of quarter ended June 30, 2019 and September 30, 2018 as reported in the accompanying Statement have been restated by the management of the Company and prepared by exercising necessary due diligence to ensure that the financial results reflect true and fair view of Company's affairs but have not been subjected to review.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Date:14/11/2019

Place: Surat



For Shivangi Parekh & Co.

Chartered Accountants

ICAI FRN: 131449W

CA. Shivangi Mehta

Proprietor

M. No.118936

UDIN: 19118936 AARACX2524

SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to the Regulations 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To

**The Board of Directors of
Zota Health Care Limited**

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Zota Health Care Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associates and joint ventures for the **quarter and half year ended September 30, 2019** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. (the "Regulation").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

Attention is drawn that the Comparative figures of quarter ended June 30, 2019 as reported in the accompanying Statement have been restated by the Company's Board of Directors, but have not been subjected to review.

Further Attention is drawn to Note no. 7 of the Statement which states the Company has incorporated wholly owned subsidiary company in Sri Lanka during the second half of Financial Year 2018-19, prior this period Company does not have any wholly owned subsidiary company. So, accordingly no consolidated accounts for the quarter and half year ended September 30, 2018 and Consolidated Cash Flow Statements for the half year ended September 30, 2018 have been prepared for the quarter and half year ended September 30, 2018.




SHIVANGI PAREKH & CO.

CHARTERED ACCOUNTANTS

4. The Statement includes the results of the following entities:
- Zota Health Care Limited (Parent)
 - Zota Healthcare Lanka (Pvt) Ltd (Subsidiary)
5. Based on our review conducted and procedures performed as stated in paragraph 3, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial statements of the subsidiary included in the consolidated unaudited financial results that reflect total assets of Rs.76,043/- as at 30.09.2019 and total revenues of Rs. Nil and Rs. Nil, total net loss after tax of Rs. 3950 and Rs. 5378 and total comprehensive loss of Rs.3950 and Rs. 5378, for the quarter and half year ended 30.09.2019, respectively, and cash flows (net) of Rs. 77623 for the half year ended 30.09.2019, as considered in the consolidated unaudited financial results. These interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, associates and joint ventures, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

For Shivangi Parekh & Co.
Chartered Accountants
ICAI FRN: 131449W



Shivangi Mehta

CA. Shivangi Mehta
Proprietor
M. No.118936

UDIN: 1911 8936 AAAACY 4273

Date:14/11/2019

Place: Surat


ZOTA HEALTH CARE LIMITED
Standalone Financial Statements


Statement of Profit & Loss for the Quarter and Half year ended 30th September, 2019

(All Amounts in ₹)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2019 (Unaudited)	30/06/2019 (Unaudited) (Refer Note-3)	30/09/2018 (Unaudited) (Refer Note-3)	30/09/2019 (Unaudited)	30/09/2018 (Unaudited)	31/03/2019 (Audited)
I. Revenue from Operations	252,874,698	216,818,937	242,229,485.00	469,693,635	432,655,522	856,294,307
II. Other Incomes	3,749,036	2,980,895	6,219,688.00	6,729,930	10,025,659	15,447,264
III. Total Revenue	256,623,733	219,799,832	248,449,173	476,423,565	442,681,181	871,741,571
IV. Expenses:						
Cost of Materials Consumed:	17,970,286	36,245,029	38,560,242.00	54,215,315	48,546,492	115,100,078
Purchases of Stock-in-Trade	145,127,967	104,758,508	155,505,158.00	249,886,475	294,693,599	527,635,052
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	16,385,934	8,946,829	(33,785,470.00)	25,332,763	(60,287,112)	(72,596,807)
Employee Benefit Expenses	25,898,652	24,351,752	22,668,241.00	50,250,404	40,275,135	88,919,072
Finance Costs	102,190	130,019	23,852.00	232,210	71,528	368,029
Depreciation / Amortisation and Depletion Expense	3,204,699	3,003,679	3,519,025.14	6,208,378	7,593,373	13,942,286
Other Expenses	33,293,988	33,986,014	25,713,449.00	67,280,002	50,996,426	119,781,409
Total Expenses	241,983,716	211,421,830	212,204,497	453,405,546	381,889,441	793,149,119
V. Profit before Exceptional items and tax from continuing operations (III-IV)	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,451
VI. Exceptional Items	-	-	-	-	-	-
VII. Profit before Extraordinary Items and Tax (V - VI)	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,451
VIII. Extra Ordinary Items	-	-	-	-	-	-
IX. Profit/(loss) before exceptional items and tax (VII-VIII)	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,451
X. Exceptional items	-	-	-	-	-	-
XI. Profit/(loss) before tax	14,640,017	8,378,002	36,244,676	23,018,020	60,791,739	78,592,451
XII. Tax Expense:						
(1) Current tax	3,680,622	2,107,643	11,804,891	5,788,265	19,796,794	23,242,539
(1.1) I.T. & DD Tax Provision Created Short/ excess	-	26,020	131,604	26,020	220,744	233,582
(2) Deferred Tax	(48,664)	(626,712)	279,809	(675,376)	469,338	402,849
XIII. Profit/ (Loss) for the period from Continuing Operations (XI - XII)	10,910,731	5,617,628	24,587,989	16,528,359	41,243,539	55,519,179
XIV. Profit/(loss) before tax from discontinued operations	-	-	-	-	-	-
XV. Tax Expense of discontinued Operations	-	-	-	-	-	-
XVI. Profit/ (Loss) from Discontinued Operations (after Tax) (XIV - XV)	-	-	-	-	-	-
XVII. Profit/ (Loss) for the Year	10,910,731	5,617,628	24,587,989	16,528,359	41,243,539	55,519,179
XVIII. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	458,729	1,150,292	-	1,609,021	-	(921,714)
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(115,453)	(289,505)	-	(404,958)	-	256,421
B (i) Items that will be reclassified to Statement of profit and loss	-	-	-	-	-	-
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-	-	-	-	-
Other comprehensive income for the year, net of tax	343,276	860,787	-	1,204,063	-	(665,293)
Total comprehensive income for the year (XVII + XVIII)	11,254,008	6,478,414	24,587,989	17,732,422	41,243,539	54,853,886
Profit attributable to:						
Owners of the parent	-	-	-	-	-	-
Non-controlling interest	-	-	-	-	-	-
Other comprehensive income attributable to:						
Owners of the parent	-	-	-	-	-	-
Non-controlling interest	-	-	-	-	-	-
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	0.44	0.23	1.00	0.67	1.68	2.26
(2) Diluted (in ₹)	0.44	0.23	1.00	0.67	1.68	2.26

For and on behalf of the Board



(Whole Time Director)
Himanshu M. Zota
(Din : 01097722)
34, Ichhanath Umra,
Surat,
Company Secretary
Ashvin Varia


(Managing Director)
Moxesh K. Zota
(Din : 07625219)
8D, Lal Bunglow, Athwalines,
Surat,
Chief Financial Officer
Vijal Mandviwala

Date: 14/11/2019
Place : Surat

Shivangi Parekh & Co.
Chartered Accountants

CA. Shivangi Mehta
Proprietor
M. No. 118936
Firm No. 131449W



Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

ZOTA HEALTH CARE LIMITED
Consolidated Financial Statements
Statement of Profit & Loss for the Quarter and Half year ended 30th September, 2019

(All Amounts in ₹)

Particulars	Quarter Ended			Half Year Ended		Year Ended
	30/09/2019	30/06/2019	30/09/2018	30/09/2019	30/09/2018	31/03/2019
	(Unaudited)	(Unaudited)	(Unaudited) (Refer Note-7)	(Unaudited)	(Unaudited) (Refer Note-7)	(Audited)
I. Revenue from Operations	252,874,698	216,818,937		469,693,635		856,294,307
II. Other Incomes	3,749,036	2,980,895		6,729,930		15,447,264
III. Total Revenue	256,623,733	219,799,832		476,423,565		871,741,571
IV. Expenses:						
Cost of Materials Consumed:	17,970,286	36,245,029		54,215,315		115,100,078
Purchases of Stock-in-Trade	145,127,967	104,758,508		249,886,475		527,635,052
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	16,385,934	8,946,829		25,332,763		(72,596,807)
Employee Benefit Expenses	25,898,652	24,351,752		50,250,404		88,919,072
Finance Costs	102,190	131,446		233,635		368,029
Depreciation / Amortisation and Depletion Expense	3,204,699	3,003,679		6,208,378		13,942,286
Other Expenses	33,297,938	33,986,014		67,283,954		119,816,458
Total Expenses	241,987,666	211,423,256		453,410,924		793,184,168
V. Profit before Exceptional items and tax from continuing operations (III-IV)	14,636,067	8,376,576		23,012,642		78,557,402
VI. Exceptional Items	-	-		-		-
VII. Profit before Extraordinary Items and Tax (V - VI)	14,636,067	8,376,576		23,012,642		78,557,402
VIII. Extra Ordinary Items	-	-		-		-
IX. Profit/(loss) before exceptional items and tax (VII-VIII)	14,636,067	8,376,576		23,012,642		78,557,402
X. Exceptional items	-	-		-		-
XI. Profit/(loss) before tax from continuing operations (IX-X)	14,636,067	8,376,576		23,012,642		78,557,402
XII. Tax Expense:						
(1) Current tax	3,680,622	2,107,642.88		5,788,265		23,242,539
(1.1) I.T. & DD Tax Provision Created Short/ excess	-	26,020.00		26,020		233,582
(2) Deferred Tax	(48,664)	(626,712.00)		(675,376)		402,849
XIII. Profit/ (Loss) for the period from Continuing Operations (XI - XII)	10,906,781	5,616,201		16,522,981		55,484,130
XIV. Profit/(loss) before tax from discontinued operations	-	-		-		-
XV. Tax Expense of discontinued Operations	-	-		-		-
XVI. Profit/ (Loss) from Discontinued Operations (after Tax) (XIV - XV)	-	-		-		-
XVII. Profit/ (Loss) for the Year	10,906,781	5,616,201		16,522,981		55,484,130
XVIII. Other Comprehensive Income						
A (i) Items that will not be reclassified to Statement of profit and loss	458,729	1,150,292		1,609,021		(921,714)
(ii) Income Tax relating to items that will not be reclassified to Statement of profit and loss	(115,453)	(289,505)		(404,958)		256,421
B (i) Items that will be reclassified to Statement of profit and loss	(9,269.01)	29.01		(9,240)		1,483
(ii) Income Tax relating to items that will be reclassified to profit and loss	-	-		-		(413)
(iii) Fair value changes on investments, net	-	-		-		-
Other comprehensive income for the year, net of tax	334,007	860,816		1,194,823		(664,223)
Total comprehensive income for the year (XVII + XVIII)	11,240,789	6,477,017		17,717,804		54,819,907
Profit attributable to:						
Owners of the parent	10,906,781	5,616,201		16,522,981		55,484,130
Non-controlling interest	-	-		-		-
Other comprehensive income attributable to:						
Owners of the parent	334,007	860,816		1,194,823		(664,223)
Non-controlling interest	-	-		-		-
Earnings per equity share of face value of ₹ 10 each						
(1) Basic (in ₹)	0.44	0.23		0.67		2.26
(2) Diluted (in ₹)	0.44	0.23		0.67		2.26

For and on behalf of the Board

(Whole Time Director) Himanshu M. Zota
(Din : 01097722)
34, Ichhanath Umra,
Surat.,

(Managing Director) Moxesh K. Zota
(Din : 07625219)
8D, Lal Bunglow, Athwalines,
Surat.,


Company Secretary
Ashvin Variya

Chief Financial Officer
Viral Mandviwala

Date: 14/11/2019
Place : Surat

Shivangi Parekh & Co.
Chartered Accountants

CA. Shivangi Mehta
Proprietor
M. No. 118936
Firm No. 131449W



Registered Office :


Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

Notes:

- 1 The above financial results for the quarter and half year ended September 30, 2019 have been reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their meeting held on November 14, 2019.
- 2 The Statutory Auditors have carried out Limited Review of the financial results for the quarter and half year ended September 30, 2019.
- 3 The Company has migrated to the main Board of National Stock Exchange w.e.f. August 19, 2019 accordingly the Company has not prepared financial results for the previous quarters. However, Comparative figures of quarter ended June 30, 2019 and September 30, 2018 have been restated by the management of the Company and prepared by exercising necessary due diligence to ensure that the financial results reflect true and fair view of Company's affairs. Financial results for the quarter ended June 30, 2019 and September 30, 2018 have not been subjected to limited review report of auditor.
- 4 The Company has evaluated its Operating segment in accordance with IND AS 108 and has concluded that it is engaged in a single operating segment.
- 5 During the reporting period; on July 29, 2019 Company has issued 7016975 bonus shares in the ratio of 4:10 [i.e. 4 (Four) fully paid up equity shares for every 10 (Ten) equity shares held.] Post this issue Earning Per Share (EPS) for all the reporting period have been restated as per IND AS 33.
- 6 The consolidated results include the result of Company's wholly owned subsidiary company Zota Healthcare Lanka (Pvt) Ltd.
- 7 The Company has incorporated wholly owned subsidiary company in Sri Lanka during the second half of Financial Year 2018-19, prior this period Company does not have any wholly owned subsidiary company. So, accordingly no consolidated accounts for the quarter and half year ended September 30, 2018 and Consolidated Cash Flow Statements for the half year ended September 30, 2018 have been prepared for the quarter and half year ended September 30, 2018.
- 8 Tax expenses for the quarter and half year ended September 30, 2019 have been calculated as per Taxation Laws (Amendment) Ordinance 2019, the income-tax is calculated at the reduced rate from the current financial year.
- 9 Figures pertaining to the previous period have been regrouped/rearranged, reclassified and restated wherever considered necessary, to make them comparable with those of current period.
- 10 On April 1, 2019, the Company has adopted IND AS 116, Leases, using modified retrospective method. Accordingly, the comparatives have not been retrospectively adjusted. The adoption of IND AS 116, did not have any material impact on the standalone results for Quarters ended September 30, 2019 and June 30, 2019 and Half-year ended on September 30, 2019.



Registered Office :

Zota House, 2/896, Hira Modi Street,
Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
Email: info@zotahealthcare.com
Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
Nr. Sachin Railway Station, Sachin,
Surat - 394 230 (Guj.) India
Ph: +91 261 2397122

ZOTA HEALTH CARE LIMITED
 Balance Sheet as at 30th September, 2019

Particulars	CONSOLIDATED		STANDALONE	
	As at	As at	As at	As at
	30th September, 2019	31st March, 2019	30th September, 2019	31st March, 2019
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
ASSETS				
(1) Non-Current Assets				
Property, plant and equipment	79,009,206	78,930,320	79,009,206	78,930,320
Intangible Assets	18,277,518	18,824,544	18,277,518	18,824,544
Capital work-in-progress	2,491,838	2,590,476	2,491,838	2,590,476
Intangible assets under development	12,933,333	12,933,333	12,933,333	12,933,333
Financial Assets				
(i) Investments	151,542,230	156,116,120	151,628,910	156,202,800
(iii) Loans	2,682,791	2,929,791	2,682,791	2,929,791
Other Non-current assets	-	-	-	-
Total Non-Current assets	266,936,915	272,324,583	267,023,595	272,411,263
(2) Current Assets				
Inventories	289,223,530	325,123,918	289,223,530	325,123,918
Financial Assets				
(i) Trade Receivables	269,690,939	220,964,038	269,690,939	220,964,038
(ii) Cash and Cash Equivalents	242,266	179,302	166,222	179,302
(iii) Bank balance other than cash and cash equivalents	12,461,270	16,763,205	12,461,270	16,763,205
(iv) Loans	47,045,863	34,380,949	47,045,863	34,380,949
Other Current Assets	38,102,188	26,330,122	38,102,188	26,330,122
Total Current assets	656,766,055	623,741,532	656,690,012	623,741,532
Total Assets	923,702,970	896,066,116	923,713,608	896,152,796
EQUITY AND LIABILITIES				
Equity				
(i) Equity Share capital	245,603,270	175,433,520	245,603,270	175,433,520
(ii) Other Equity	431,758,250	513,818,636	431,805,671	513,852,615
Total Equity	677,361,520	689,252,156	677,408,941	689,286,135
Liabilities				
Non-Current Liabilities				
Financial Liabilities				
(i) Borrowings	-	-	-	-
Provisions	7,669,115	7,564,955	7,632,331	7,564,955
(1) Deferred tax liabilities (Net)	1,821,899	1,146,522	1,821,899	1,146,522
Total non-current liabilities	9,491,014	8,711,477	9,454,230	8,711,477
Current liabilities				
Financial Liabilities				
(i) Borrowings				
(ii) Trade payables				
- Total outstanding dues of micro enterprises and small enterprises	38,950,369	2,044,021	38,950,369	2,044,021
- Total Outstanding dues of Creditors other than micro enterprises and small enterprises	144,831,671	159,639,665	144,831,671	159,639,665
Other Current liabilities	12,851,643	5,161,656	12,851,643	5,248,336
Provisions	40,216,754	31,257,140	40,216,754	31,223,161
Total current liabilities	236,850,437	198,102,482	236,850,437	198,155,183
Total Liabilities	246,341,451	206,813,960	246,304,667	206,866,661
Total Equity and Liabilities	923,702,971	896,066,116	923,713,608	896,152,796

For and on behalf of the Board


 (Whole Time Director)
 Himanshu M. Zota
 (Din : 01097722)
 34, Ichhanath Umra,
 Surat.,


 (Managing Director)
 Moxesh K. Zota
 (Din : 07625219)
 8D, Lal Bunglow, Athwalines,
 Surat.,



 Company Secretary
 Ashvin Variya


 Chief Financial Officer
 Viral Mandviwala



Shivangi Parekh & Co.
 Chartered Accountants


 CA. Shivangi Mehta
 Proprietor
 M. No. 118936
 Firm No. 131449W



Date: 14/11/2019
 Place : Surat

Registered Office :

Zota House, 2/896, Hira Modi Street,
 Sagrampura, Surat - 395 002 | Ph: +91 261 2331601
 Email: info@zotahealthcare.com
 Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
 Nr. Sachin Railway Station, Sachin,
 Surat - 394 230 (Guj.) India
 Ph: +91 261 2397122

ZOTA HEALTH CARE LIMITED
 Cash Flow Statement For the Half Year Ended 30th September, 2019

(Amount in ₹)

PARTICULARS	Consolidated		Standalone	
	Half year ended 30th September, 2019 (Unaudited)	Half year ended 30th September, 2018 (Unaudited) <i>(Refer Note-7)</i>	Half year ended 30th September, 2019 (Unaudited)	Half year ended 30th September, 2018 (Unaudited)
A CASH FLOW FROM OPERATING ACTIVITIES				
Net Profit Before Tax as per Statement of Profit and Loss	23,012,642		23,018,020	60,791,740
Adjusted for:				
Exceptional items				
Depreciation / Amortisation and Depletion Expense	6,208,378		6,208,378	7,593,373
Interest on Unsecured loan				4,328
Interest on Fixed Deposits	(5,492,806)		(5,492,806)	(8,635,333)
Interest on GEB Deposits	23,450		23,450	
Operating Profit before Working Capital Changes	23,751,664		23,757,042	59,754,108
Adjusted for:				
Trade Payables	22,098,354		22,098,354	41,692,075
Provisions-Current Liabilities	10,560,572		10,602,614	(18,520,785)
Borrowings-Current Liabilities				
Provisions - Non-Current	104,160		67,376	2,209,877
Current Liabilities	7,689,987		7,603,307	9,298,208
Trade Receivables	(48,726,901)		(48,726,901)	(33,057,666)
Loans	(12,664,914)		(12,664,914)	25,855,473
Inventories	35,900,388		35,900,388	(69,593,488)
Other Current Assets	(11,772,066)		(11,772,066)	(14,086,361)
Changes in Working Capital	3,189,580		3,108,158	(56,202,668)
Cash Generated from Operations	26,941,243		26,865,199	3,551,440
Taxes Paid	(6,219,243)		(6,219,243)	(20,017,538)
Net Cash Flow from/(Used in) Operating Activities (A)	20,722,000		20,645,956	(16,466,098)
B CASH FLOW FROM INVESTING ACTIVITIES				
Purchase of Intangible Assets				
Decrease in Long Term Loans & Advances	247,000		247,000	
Interest on Fixed Deposits	5,492,806		5,492,806	8,635,333
Interest on GEB Deposits	(23,450)		(23,450)	
Purchase of Tangible Assets	(5,641,601)		(5,641,601)	(10,997,242)
Non-current Investments	4,573,890		4,573,890	76,874,774
Net Cash Flow (Used in) Investing Activities (B)	4,648,645		4,648,645	74,512,865
C CASH FLOW FROM FINANCING ACTIVITIES				
Interest on Unsecured Loan				(4,328)
Dividend Paid	(24,560,327)		(24,560,327)	(52,630,056)
Tax on Dividend	(5,049,289)		(5,049,289)	(10,714,242)
Net Cash Flow from / (Used in) Financing Activities (C)	(29,609,616)		(29,609,616)	(63,348,626)
Net Increase/(Decrease) in Cash & Cash Equivalents (A+B+C)	(4,238,971)		(4,315,015)	(5,301,859)
Opening Balance of Cash and Cash Equivalents	33,705,709		16,942,506	24,620,927
Closing Balance of Cash and Cash Equivalents	12,703,536		12,627,492	19,319,068


For and on behalf of the Board

H.M. Zota (Whole Time Director)
 Himanshu M. Zota
 (Din : 01097722)
 34, Ichhanath Umra, 8D, Lal Bungalow, Athwalines,
 Surat.

M. K. Zota (Managing Director)
 Moxesh K. Zota
 (Din : 07625219)
 Surat.


Ashwin Variya Company Secretary
 Ashwin Variya

Viraj Mandviwala Chief Financial Officer
 Viraj Mandviwala



Shivangi Parekh & Co.
 Chartered Accountants

S. Parekh
 CA. Shivangi Mehta
 Proprietor
 M. No. 118936
 Firm No. 131449W



Registered Office :

Zota House, 2/896, Hira Modi Street,
 Sagrapura, Surat - 395 002 | Ph: +91 261 2331601
 Email: info@zotahealthcare.com
 Web : www.zotahealthcare.com

Plant :

Plot no. 169, Surat Special Economic Zone,
 Nr. Sachin Railway Station, Sachin,
 Surat - 394 230 (Guj.) India
 Ph: +91 261 2397122